Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.
Authors
Bassi, Jessica
Giannini, Olivier
Silacci-Fregni, Chiara
Pertusini, Laura
Hitz, Paolo
Terrot, Tatiana
Franzosi, Yves
Saliba, Christian
Meury, Marcel
Dellota, Exequiel A
Dillen, Josh R
Hernandez, Patrick
Czudnochowski, Nadine
Cameroni, Elisabetta
Beria, Nicola
Ventresca, Mariangela
Badellino, Alberto
Lavorato-Hadjeres, Soraya
Lecchi, Elisabetta
Bonora, Tecla
Mattiolo, Matteo
Trinci, Guido
Garzoni, Daniela
Bonforte, Giuseppe
Forni-Ogna, Valentina
Giunzioni, Davide
Berwert, Lorenzo
Ceschi, Alessandro
Cippà, Pietro
Corti, Davide
Lanzavecchia, Antonio
Publication Date
2022Journal Title
PLoS One
ISSN
1932-6203
Publisher
Public Library of Science (PLoS)
Volume
17
Issue
2
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Bassi, J., Giannini, O., Silacci-Fregni, C., Pertusini, L., Hitz, P., Terrot, T., Franzosi, Y., et al. (2022). Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.. PLoS One, 17 (2) https://doi.org/10.1371/journal.pone.0263328
Description
Funder: Swiss Kidney Foundation
Abstract
Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-naïve hemodialysis patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity. Patients followed up to 7 months after vaccination showed a rapid decay of the antibody response with an average 21- and 10-fold reduction of neutralizing antibodies to vaccine-matched SARS-CoV-2 and Delta variant, which increased the fraction of non-responders to 84% and 90%, respectively. These data indicate that dialysis patients should be prioritized for additional vaccination boosts. Nevertheless, their antibody response to SARS-CoV-2 must be continuously monitored to adopt the best prophylactic and therapeutic strategy.
Keywords
Research Article, Biology and life sciences, Medicine and health sciences
Sponsorship
MRC (via Imperial College London) (MR/W005611/1)
Identifiers
pone-d-21-33759
External DOI: https://doi.org/10.1371/journal.pone.0263328
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333858
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk